Navigation Links
Mylan Announces Final FDA Approval for Zaleplon Capsules
Date:6/9/2008

PITTSBURGH, June 9 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that its subsidiary, Genpharm ULC, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zaleplon Capsules, 5 mg and 10 mg.

Zaleplon Capsules are the generic version of King Pharmaceuticals' Sonata(R) Capsules, which had U.S. sales of approximately $88 million for the 12 months ending March 31, 2008, according to IMS Health.

This product is shipping immediately and will be sold under the Mylan Pharmaceuticals brand.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
2. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
3. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
4. Mylan Declares Quarterly Preferred Stock Dividend
5. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
6. Mylan Announces Final FDA Approval for Trandolapril Tablets
7. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
8. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
9. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
10. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
11. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... the National Association of Music Merchants (NAMM) winter trade show, Booth #2876, at ... Etymotic’s ER•4® has long been the gold standard for high-definition, in-ear earphones. This ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... online continuing education for EMS and firefighting professionals, has released four new continuing ... These new courses are taught live in an online classroom and meet the ...
(Date:1/17/2017)... ... January 17, 2017 , ... SensorInsight ®, an Internet ... in the U.S.A. to offer Internet of Things (IoT) solutions based on ... sensor deployments such as monitoring solutions used to detect potentially hazardous conditions in ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Livionex, Inc., a ... of a double blind clinical study for its dental gel that shows significant reduction ... brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... ranked among the top US security companies for consecutive years, today announced the ... brings a year-long independent board nomination process to a close and positions Lynx ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan 17, 2017 Research and Markets ... by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product ... Global Forecast to 2021" report to their offering. ... The global active pharmaceutical ... from USD 157.95 Billion in 2016, growing at a CAGR of ...
(Date:1/17/2017)... WARSAW, Ind. , Jan. 17, 2017  Zimmer ... leader in musculoskeletal healthcare , today announced ... capitalizes on the strength of the Zimmer Biomet ... D. Delp will assume the position of ... of the Company. Mr. Delp previously served as Zimmer ...
(Date:1/17/2017)... , Jan. 17, 2017 Tempus, ... cancer care, and University Hospitals Seidman Cancer Center ... by making genomic data, advanced molecular analysis and ... researchers, physicians and healthcare providers. ... provide genomic and transcriptomic sequencing and analysis for ...
Breaking Medicine Technology: